FindTrial
Sign In

Effect of Clopidogrel (Plavix) on Postoperative Bleeding in Patients undergoing Coronary Artery Bypass Surgery. A prospective randomized controlled study.

Effect of Clopidogrel (Plavix) on Postoperative Bleeding in Patients undergoing Coronary Artery Bypass Surgery. A prospective randomized controlled study. - Plavix study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON29792
Enrollment
150
Registered
2006-05-23
Start date
2006-06-01
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Catharina-ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients who are using clopidogrel at least 5 days before surgery with a dose of 75mg clopidogrel without loading dose, with or without concomitant use of aspirin. Or patients who received a loading dose of 300-600mg clopidogrel 24 hours before CABG, with or without concomitant use of aspirin

Exclusion criteria

Exclusion criteria: concomitant use of coumarine/heparine derivates; pre-existing bleeding disorders; thrombocytopenia; renal and hepatic failure; end-stage heart failure; emergency bypass surgery; concomitant valvular or other cardiac procedures; re-operation; off-pump CABG

Design outcomes

Primary

MeasureTime frame
Blood loss, transfusions and rethoracotomies. Predictive value of TEG—

Secondary

MeasureTime frame
Death, myocardial infarction, stroke, respiratory failure, renal failure requiring dialysis, mediastinitis, wound infection, readmission rates within 30 days from discharge, and ICU and hospital lengths of stay—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)